LEFP
NBIX icon

Leading Edge Financial Planning’s Neurocrine Biosciences NBIX Stock Holding History

Leading Edge Financial Planning’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$213K Buy
1,619
+2
+0.1% +$265 0.04% 71
2025
Q4 		$229K Buy
1,617
+2
+0.1% +$290 0.05% 59
2025
Q3 		$227K Buy
+1,615
New +$219K 0.06% 58

Other funds holding NBIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Leading Edge Financial Planning's NBIX Position: Q1 2026 in Review

Leading Edge Financial Planning increased its Neurocrine Biosciences (NBIX) stake by 0.12% in Q1 2026, buying an estimated $265 and bringing the position to 1,619 shares worth $213K. The position accounts for 0.04% of the portfolio, ranked #71.

Leading Edge Financial Planning first reported a position in NBIX in Q3 2025 and has held it in 3 quarters since. The position peaked at $229K in Q4 2025. 694 funds tracked by Wall St. Rank hold NBIX as of Q1 2026.

  • Leading Edge Financial Planning held 1,619 shares of Neurocrine Biosciences worth $213K as of Q1 2026.
  • Leading Edge Financial Planning bought 2 Neurocrine Biosciences shares in Q1 2026, an estimated $265.
  • Neurocrine Biosciences made up 0.04% of Leading Edge Financial Planning's portfolio in Q1 2026, its #71 holding.
  • Leading Edge Financial Planning first reported a position in Neurocrine Biosciences in Q3 2025 and has held it in 3 quarters since.
  • Leading Edge Financial Planning's Neurocrine Biosciences position peaked at $229K in Q4 2025.
  • 694 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2026.

Based on Leading Edge Financial Planning's 13F filing for Q1 2026, filed 12 May 2026.